BCMA-GPRC5D CAR-T cells
/ Shenzhen University General Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 16, 2024
HEM-ONCO-028: BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1/2 | N=10 | Recruiting | Sponsor: Shenzhen University General Hospital
IO biomarker • New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1